SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses potential integrations and real-world asset (RWA) applications. Conversations revolve around potential partnerships, particularly with $SUI and $WLFI, alongside speculation about future revenue and tokenomics. Some users are also anticipating a broader altcoin season, contingent on $BTC dominance declining.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

CAW CRYPTO is trending due to strong community support and its growing presence across multiple blockchains. The community emphasizes its organic growth, deflationary mechanisms, and growing partnerships, rallying behind the "crow with knife" meme.

PG&E Corp. operates as a holding company, which engages in generation, transmission, and distribution of electricity and natural gas to customers. It specializes in energy, utility, power, gas, electricity, solar and sustainability. The company was founded in 1995 and is headquartered in Oakland, CA.

PG&E Corp.

PG&E Corp. is trending amidst community discussion around unusual options activity and potential market manipulation. Some view the dip as a buying opportunity, citing the company's stable, defensive characteristics and growth potential in California's energy market, particularly with data centers and EV infrastructure. However, others remain cautious due to wildfire liabilities and regulatory pressures, noting the stock's underperformance and association with the broader utility sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network ($ZBCN) is trending amid community excitement around potential partnerships and upcoming announcements, with speculation about integrations with major players like Ripple and potential listings on tier-1 exchanges such as Coinbase. The community is also discussing staking opportunities and the potential for real-world adoption of ZBCN's technology. Bullish sentiment is high, with many anticipating a significant price increase and new all-time highs.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending as community members highlight its potential for cross-chain automation and recent integrations, while also mentioning a future catalyst that could increase its value. Some users are discussing accumulation strategies, with many believing it's undervalued and expressing excitement about its long-term prospects. The community is also looking forward to the sunsetting of $PRQ, which some believe will allow $REACT to trade more freely.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals ($CRML) is trending due to speculation around potential U.S. government investment in its Greenland rare earths mine, with community members citing a Reuters report and comparing it to similar situations with $LAC. Community discussion revolves around the potential for a significant price increase, the company's ownership structure, and the upcoming BFS (Bankable Feasibility Study). Some traders express bullish sentiment and anticipate substantial gains, while others caution against potential volatility and profit-taking.

About Cartesi (CTSI)  Cartesi enables developers to build appchain rollups with any code, while benefiting from the security of Ethereum. It bridges the gap between traditional software and blockchain by bringing decades of mature operating systems, programming languages, libraries, and tools to decentralized applications.  Cartesi aims to provide the technological foundation from which builders, entrepreneurs, and projects will develop decentralized applications. The Cartesi technology suite is currently comprised of:  Cartesi Rollups: Cartesi Rollups is an app-specific execution environment that can be deployed as a L2, L3, or as sovereign rollups. The combination of an Optimistic Rollups framework and the Cartesi Machine Emulator enables the development of smart contracts and dApps using any package or library that is available for Linux. This allows developers to break free from the scalability limitations of the Ethereum Virtual Machine (EVM), and brings the rise of a new blockchain era to handle real-life and complex use cases.  Cartesi Machine: A RISC-V-based virtual machine (altVM) running Linux OS, enabling complex computations and seamless dApp development by expanding the design space and leveraging 40 years of software programming advancements.  CartesiScan: Cartesiscan is the explorer used for viewing blockchain transactions on Cartesi appchain rollups.  Cartesi Explorer: The Cartesi Explorer is a product that allows CTSI users to interact with the governance system and stake CTSI.  Fraud Proof System - DAVE (following PRT): Dave is a permissionless, interactive fraud-proof system. Cartesi’s algorithm further optimizes the fraud proof mechanism to achieve the best balance between security, decentralization, and activity.  What Makes Cartesi Unique  The infrastructure of the internet took 40 years, billions of hours of work, and trillions of dollars to build. With Cartesi, developers gain access to these decades of meticulously refined operating systems, programming languages, software libraries, and tools, paving the way for the next generation of blockchain applications.  Cartesi empowers Ethereum rollups with real-world software and strong guarantees.  Cartesi designed its own Optimistic Rollups framework embedding its own non-EVM virtual machine based on RISC-V.  Leverage decades‑proven software ecosystems: The Cartesi Machine enables full Linux and RISC‑V stack execution in a composable, verifiable rollup environment.  Cartesi’s architecture is optimized for app‑specific rollups, providing scalable and secure chains tailored to each dApp’s needs, backed by a state-of-the-art fraud proof system, properly categorized as Stage-2 according to L2BEAT.  Token Utility  Governance: CTSI holders can currently stake their tokens to earn rewards and participate in ecosystem governance.   Validator Marketplace: Applications built on Cartesi need validators to monitor and ensure the trustworthiness of transactions. The Validator Marketplace is a decentralized matchmaking service that connects applications with validation service providers. The Validator Marketplace will leverage the CTSI token as a primary means of incentivization in three important ways:  1. Validators will be required to stake CTSI in order to participate, ensuring performance and honest behavior.  2. CTSI holders will be able to delegate their CTSI to experienced validators, allowing tokenholders to share in validation fees without running their own nodes.  3. Token holders can use their CTSI to “buy” a stake in a dApp’s future growth, signaling support for dApps they believe will succeed. The earlier a backer “gets in” on a dApp, the more they are rewarded as that dApp gains traction.  The Validator Marketplace creates a direct link between Cartesi dApp usage and CTSI token demand, enabling token holders to share in the growth and success of the ecosystem.

Cartesi

Cartesi (CTSI) is trending as community members discuss its potential for a breakout, focusing on technical indicators and positive vibes. Some anticipate significant gains and highlight the project's strong fundamentals, including its focus on long-term development. The community is also actively sharing links to Cartesi's Twitter and documentation.

Pebblebrook Hotel Trust is a real estate investment trust, engages in investments and acquisitions in hotel properties. Its hotels are located in markets like Atlanta, Georgia, Boston, Massachusetts, Chicago, Illinois, Key West, Miami and Naples, Florida, Los Angeles, San Diego and San Francisco, California, Nashville, Tennessee, New York, New York, Philadelphia, Pennsylvania, Portland, Oregon, and Seattle, Washington. The company was founded by Jon E. Bortz on October 2, 2009 and is headquartered in Bethesda, MD.

Pebblebrook Hotel Trust

Pebblebrook Hotel Trust is trending as investors digest recent analyst rating adjustments and monitor the company's strategic asset sales in San Francisco and Portland. The community is focused on how these sales impact Pebblebrook's balance sheet and future performance amid broader concerns about the REIT sector and interest rate sensitivity. Discussions also include the CEO's recent share purchases, which some see as a positive signal.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

Black Titan Corp. ($BTTC) is trending due to a recent merger and after-hours price action, leading to speculation about a potential short squeeze. The community is actively discussing the stock's low float and high insider ownership, with some anticipating a continued upward trend. Some traders are also pointing to a potential fat-finger buying incident due to the stock's similarity in name to Bitcoin.

Penguin Solutions, Inc. engages in the design and manufacture of enterprise solutions for the computing, memory, and LED markets. It operates through the following segments: Advanced Computing, Integrated Memory & Optimized LED. The Advanced Computing segment consists of platform solutions and services for high-performance computing, artificial intelligence, machine learning, and modeling for technology research. The Integrated Memory segment provides performance and reliable memory solutions through the design, development, and advanced packaging to extended lifecycle products. The Optimized LED segment offers a broad portfolio of application-optimized LEDs focused on improving lumen density, intensity, efficacy, optical control, and reliability. The company was founded in 1988 and is headquartered in Milpitas, CA.

Penguin Solutions Inc.

Penguin Solutions ($PENG) is trending as investors anticipate upcoming earnings, with some noting large options orders and potential for a setup next week. Bullish sentiment is fueled by the company's strong year-to-date performance, a reiterated "Buy" rating from Rosenblatt, and expectations of exceeding fiscal 2025 guidance. The community also discusses PENG's potential to benefit from the growing AI infrastructure market and key relationships within the tech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) closed at $85.31 in the latest trading session, marking a +1.98% move from the prior day.

MRK Stock Up Nearly 14% So Far This Week: What's Driving It?

Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.

AstraZeneca (AZN) plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq, the pharmaceutical giant announced on Monday.The move is part of the company’s efforts to expand its access to capital, including in the U.S. Nasdaq-listed ADRs of the company traded 1% higher in the pre-market session at the time of writing.Following the implementation of the new and harmonized listing structure, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE), the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-harmonise-its-listing-structure-across-the-london-stock-exchange-nasdaq-stockholm-and-new-york-stock-exchange.html">said</a>.Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders, while remaining headquartered in the U.K. The plan will now be put to a vote on November 3.On Stocktwits, retail sentiment surrounding <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> remained within the ‘bearish’ territory while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:578/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_6_49_19_AM_png_073b67d335.webp" alt="AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="578" height="62"><figcaption>AZN's Sentiment Meter and Message Volume as of 6:49 a.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>AstraZeneca stated that the U.S. has the world’s largest and most liquid public markets by capitalization. The new listing structure will not alter the company’s status as a U.K.-listed, headquartered, and tax-resident company, the company added.In 2024, the United States accounted for 43% of AstarZeneca’s total revenue. The U.S. accounted for $23.23 billion in revenue while Europe accounted for 23% of total revenue, or $12.19 billion.In July, the company also announced a $50 billion investment in the U.S. by 2030, which would include the expansion of its research and development facility in Maryland, as well as manufacturing facilities for cell therapy in Rockville, Maryland, and Tarzana, California, among others.It had then stated that the investments would help it achieve its goal of reaching $80 billion in total revenue by 2030, with half of that revenue to be generated in the U.S. AZN shares are up by 13% this year but down by over 5% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-stellantis-24000-alfa-romeo-vehicles/chDM6PoR37x">US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Plans Ordinary Share Listing In US – Find Out More On The Harmonized Listing Structure

Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders. 

Equity

Michel Demaré, Chair of AstraZeneca, stated that enabling a global listing structure would allow the company to reach a broader mix of global investors and make it even more attractive to all its shareholders. 


Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

U.S. President Donald Trump said on Thursday that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting Oct. 1 unless manufacturers are actively building plants in the country.&nbsp;As part of a series of late-night posts on Truth Social on Thursday,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/115267512131958759">Trump said</a> the exemption will apply only to firms that have “broken ground” or are “under construction.” “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”&nbsp;The announcement intensifies the administration’s push to shift drug manufacturing to the U.S. Last month, Trump said the U.S. would begin with a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-plans-gradual-tariff-hike-on-imported-pharma-to-250-over-18-months-to-boost-us-production/chr1KgrRd2x">“small tariff”</a> on imported drugs before raising duties to 150% within 18 months and ultimately to 250%.&nbsp;Pharmaceuticals had previously been exempt from Trump’s reciprocal tariff program; however, the new duties will apply to prescription drugs, biologics, specialty medicines, and over-the-counter products, except for generic drugs, which remain excluded.Major drugmakers have responded unevenly.&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly</a> has committed more than $50 billion since 2020 to U.S. expansion, including $27 billion for four new “mega sites.” The company supports maintaining the U.S. as the “world’s leading destination for biopharmaceutical research and manufacturing” and agrees with the administration’s goal of more fairly sharing drug costs across developed countries, even as it warns that broad tariffs could raise costs and limit access.Lilly’s stream on Stocktwits gained traction late Thursday after Trump’s announcement, with sentiment tilting ‘bullish’ as retail traders bet that the company would benefit from the latest federal policy. “$LLY did great with plant announcement in houston this week. They wont have tariffs,”&nbsp;<a href="https://stocktwits.com/Gorohanada/message/630073275">said</a> one user.Several users noted that Novo Nordisk, Regeneron and Thermo Fisher also have U.S. sites that could qualify. Some argued investors misunderstand Novo’s footprint, contributing to its recent weakness despite likely exemptions.<stembedurl>https://stocktwits.com/3rdtimeretired/message/630071784</stembedurl><stembedurl>https://stocktwits.com/Bullish_Trader555/message/630067344</stembedurl><stembedurl>https://stocktwits.com/oldmanrizzer/message/630072277</stembedurl>AstraZeneca and Roche each announced plans this summer to invest $50 billion in new or expanded facilities across multiple states. Merck has invested more than $12 billion in U.S. manufacturing since 2017 and plans to invest an additional $9 billion by 2028, while Biogen has pledged $2 billion to upgrade its North Carolina plants.Others have taken a more cautious stance. Pfizer stated in March that it could shift overseas production to existing U.S. sites if necessary, but has not committed to new investment, whereas Novo Nordisk has yet to announce major U.S. projects.&nbsp;Trump’s Thursday night post followed the launch of fresh national security probes into imports of robotics, industrial machinery, and medical devices. The Commerce Department said on Wednesday that it launched investigations on Sept. 2 to determine if these imports could pose a risk to U.S. national security.&nbsp;On Stocktwits, retail sentiment for the SPDR S&amp;P Biotech ETF (XBI) was ‘bearish’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/XBI">XBI</a> has risen 6.5%. So far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump answers questions after making an announcement on “significant medical and scientific findings for America’s children” in the Roosevelt Room of the White House on September 22, 2025. (Photo by Andrew Harnik/Getty Images)

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America

Generic drugs remain exempt, while duties will apply to prescription, biologic, specialty and over-the-counter medicines.

Astrazeneca (AZN) Declines More Than Market: Some Information for Investors

The latest trading day saw Astrazeneca (AZN) settling at $73.53, representing a -2.43% change from its previous close.

Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?

Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc - ADR

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

AZN
AstraZeneca PLC

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AZN News

AZN AstraZeneca PLC